What Globe Biotech does

Globe Biotech Limited is a Bangladeshi biopharmaceutical company established in 2015 as a subsidiary of Globe Pharmaceuticals Group of Companies Limited, focused on developing affordable biologics, biosimilars, vaccines, and gene/cell therapy products for domestic and international markets. The company operates an integrated platform spanning R&D, API manufacturing, cGMP-compliant fill-finish production (capable of 25 million finished doses per year), animal research, and engineering/IT facilities, all headquartered in Dhaka with an additional animal research facility in Rupganj, Narayanganj.

The company's technology stack is built around a proprietary platform enabling development of novel biomolecules, monoclonal antibodies, fusion proteins, hormones, blood factors, cytokines, therapeutic oligos, vaccines, and gene therapy products, with published research in mRNA vaccine and liposomal drug manufacturing appearing in Scientific Reports (Nature). Its portfolio includes 8-10 biosimilar drug candidates (including Aldesleukin, Filgrastim, Etanercept, Adalimumab, Bevacizumab, Trastuzumab, Somatropin, Darbepoetin, Erythropoietin alpha, and Rituximab) in clinical trials, two COVID-19 vaccine candidates (BANCOVID and BANGAVAX), a SARS-CoV-2 detection kit, and programs in regenerative medicine, cell therapy, and RNAi-based gene therapy.

Commercially, Globe Biotech generates no disclosed revenue and is effectively pre-revenue, with all biosimilars still in clinical stages and vaccines at or before human-trial stage. Go-to-market relies on appointed channel partners — GenVac (BD) Limited for global marketing and clinical trial facilitation, and Anmol Health Care for Nepal — alongside direct institutional engagement with the Bangladesh Government. Pricing is not publicly disclosed, and the stated mission is to deliver quality biologics at affordable prices to the global population, positioning the company as a low-cost biosimilar and vaccine manufacturer for South Asian and emerging-market healthcare systems.

Name

Globe Biotech

Legal name

Globe Biotech Limited

Website

https://globe-biotech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Globe Biotech Limited is a Bangladeshi biopharmaceutical subsidiary of Globe Pharmaceuticals Group that develops affordable biosimilars, vaccines (including COVID-19 candidates BANCOVID and BANGAVAX), gene/cell therapies, and diagnostics for domestic and emerging-market healthcare systems.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Biosimilar Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Biologics manufacturing
• Biosimilar drugs
• Vaccine development
• Monoclonal antibody production
• Cell and gene therapy

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Biosimilar Drugs: Development and sale of 8 biosimilar drugs currently under clinical trial process, with several more under development. Revenue will be generated upon regulatory approval and commercialization.
2. COVID-19 Vaccines: BANCOVID vaccine development and distribution. Three COVID-19 vaccine candidates enlisted by WHO. Bangladesh approved for human trials (BANGAVAX).
3. Diagnostic Kits: Development and production of molecular diagnostics solutions including COVID-19 detection kits for unmet situations.
4. Cell and Gene Therapy Products: Regenerative medicine and cell therapy products using stem cells, engineered cells for disease treatment and cell replacement therapies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Globe Biotech Limited is a Bangladeshi biotechnology research and manufacturing company that develops biosimilar biologics, vaccine candidates, molecular diagnostics, and cell/gene therapy products using its proprietary biologics platform technology. Its portfolio includes ten biosimilar drug candidates under clinical trial (e.g., Adalimumab, Trastuzumab, Bevacizumab, Etanercept), COVID-19 vaccine candidates BANCOVID and BANGAVAX, and a COVID-19 detection kit. The company operates vertically integrated cGMP-compliant R&D, API manufacturing, and fill-finish (25 million doses/year) facilities.

Product overview

Globe Biotech Limited is a Bangladeshi biotech company offering a portfolio of 10 biosimilar drugs (Aldesleukin, Filgrastim, Etanercept, Adalimumab, Bevacizumab, Trastuzumab, Somatropin, Darbepoetin, Erythropoietin alpha, Rituximab), all currently under clinical trial, alongside vaccine candidates including BANCOVID and BANGAVAX. The company operates across five core therapeutic areas: Biologics (engineered monoclonal antibodies, fusion proteins, hormones, blood factors, cytokines, therapeutic oligos), Cell Therapy (engineered cell, stem cell, matrix engineering, regenerative medicine), Gene Therapy and RNAi technology, Regenerative Medicine, and Diagnostics (molecular diagnostic kits). The company also provides a customer-facing Product Authenticity Verification System for validating product authenticity via security codes.

Differentiator

Problem solved

Functional benefit

Products and services

• BANCOVID COVID-19 vaccine candidate developed by Globe Biotech Limited, listed by WHO in the draft landscape for COVID-19 vaccines; underwent clinical trials in collaboration with ICDDR,B. Intended for prevention of COVID-19 outbreaks.
• BANGAVAX COVID-19 vaccine candidate that received Bangladesh Medical Research Council (BMRC) approval to start human trials, intended for prevention of COVID-19.
• COVID-19 Detection Kit Molecular diagnostic solution for SARS-CoV-2 detection developed by Globe Biotech, designed to support unmet diagnostic situations such as the COVID-19 pandemic.
• Biosimilar Drug Pipeline (Adalimumab, Bevacizumab, Trastuzumab, Rituximab, Etanercept, Filgrastim, Aldesleukin, Somatropin, Darbepoetin, Erythropoietin alpha) Portfolio of ten biosimilar drug candidates developed using Globe Biotech's proprietary platform technology for biologics manufacturing, covering oncology (Bevacizumab, Trastuzumab, Rituximab), immunology (Adalimumab, Etanercept), hematology (Filgrastim, Erythropoietin alpha, Darbepoetin), endocrinology (Somatropin), and immuno-oncology (Aldesleukin); currently under clinical trial process with commercialization planned post-regulatory approval.
• Product Authenticity Verification System Online verification portal (https://globe-biotech.com/verify/) that allows customers to validate Globe Biotech products by entering 12-digit security codes from product packaging holograms, supporting anti-counterfeiting and patient safety.

Quantifiable outcome

• 25 million finished doses per year production capacity
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Anmol Health Care (Nepal)minorChannel Partner/ Reseller/ Distributor · 1 October 2020Anmol Health Care collaborated with Globe Biotech limited Bangladesh for Covid 19 Vaccine BANCOVID for supply registration and distribution in Nepal market.
• GenVac (BD) LimitedcoreChannel Partner/ Reseller/ DistributorGlobe Biotech Limited appointed GenVac (BD) Limited as marketing channel partner for products, services, and for facilitating to conduct clinical trials on various parts of the world.
• Dhaka University (DU)coreStrategic or Co-development PartnerDhaka University will develop vaccines and research new medicines in collaboration with Globe Biotech Limited, the Bangladeshi biotech firm that produced the Covid-19 vaccine Bangavax.
• ICDDRBcoreStrategic or Co-development PartnerICDDRB (International Centre for Diarrhoeal Disease Research, Bangladesh) will conduct clinical trial of the Covid vaccine Bancovid invented by Globe Biotech.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Biocon: India-based global biopharmaceutical company that develops and manufactures biosimilars (insulin, monoclonal antibodies), therapeutic proteins, and novel biologics — directly comparable product portfolio to Globe Biotech's biosimilars pipeline including monoclonal antibodies such as Adalimumab, Trastuzumab, and Rituximab.
• Samsung Bioepis: South Korea-based biosimilar developer with approved biosimilars across immunology, oncology, and ophthalmology — directly comparable to Globe Biotech's biosimilars-focused pipeline targeting similar reference biologics including etanercept, adalimumab, and bevacizumab.
• Biological E: India-headquartered vaccine and biologics manufacturer with WHO-prequalified vaccines and biosimilar pipeline including erythropoietin and other biologics — comparable vertically integrated facilities, emerging-market focus, and similar biosimilars/vaccine portfolio overlap.
• Bharat Biotech: India-based vaccine and biologics manufacturer with WHO-prequalified vaccines, biosimilars, and biologics pipeline — comparable to Globe Biotech in its South-Asia base, vaccine R&D focus, and biologics manufacturing scale targeting emerging markets.
• Dr. Reddy's Laboratories: India-based global pharmaceutical company with biosimilars and biologics in development, including rituximab and other oncology/immunology biosimilars that directly overlap Globe Biotech's pipeline — comparable emerging-market origin and biosimilars targeting strategy.
• Panacea Biotec: India-based vaccine and biopharmaceutical company with WHO-prequalified vaccines and biosimilars pipeline including oncology biologics — comparable emerging-market South-Asian base, vaccine and biologics manufacturing capability, and WHO-aligned regulatory focus.
• Incepta Pharmaceuticals: Bangladesh-based leading pharmaceutical and biologics manufacturer with strong domestic market presence and growing biosimilars/vaccines capability — most direct Bangladesh-based peer sharing the same domestic market, distribution channels, and affordable-medications positioning.

Broad incumbents

• Moderna: US-headquartered mRNA vaccine and therapeutics company whose core mRNA platform technology directly parallels Globe Biotech's mRNA vaccine manufacturing capability published in Nature Scientific Reports — comparable underlying mRNA platform technology though vastly larger in scale and product reach.
• Zydus Cadila (Cadila Healthcare): India-based biopharmaceutical company with biosimilars, vaccines, and novel biologics including its own COVID-19 vaccine ZyCoV-D — comparable biosimilars pipeline, Indian regulatory approvals, and global expansion ambition similar to Globe Biotech.
• Serum Institute of India: World's largest vaccine manufacturer by doses, offering a much broader vaccine and biologics portfolio — comparable in terms of emerging-market vaccine supply mission, WHO enlistments, and large-scale fill-finish capacity that exceeds Globe Biotech's 25M dose facility.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/globebiotechbd
• Facebookfacebook.com/globebiotechlimited
• LinkedInlinkedin.com/company/globebiotechlimited

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Globe Biotech